Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ORGANIZATION
ORGANIZATION
- Keizai Doyukai’s Hasegawa Appointed National Strategy Council’s Private Sector Member, Vows “All-Out Effort
October 19, 2011
- JGA President Sawai Insists on Keeping 70% Rule for New Generics
October 19, 2011
- Dispensing Fees May Be Cut to Enable Hike in Medical Fees: Mr Urushibata of Chuikyo
October 18, 2011
- Vaccine Industry Must Continue to Present Proposals t oGov’t: Mr Fushimi of JAVI
October 18, 2011
- JPA Opposes TPP on Fears of Drug Safety
October 14, 2011
- Osteoporosis Foundation Survey Shows Patient Interest in Monthly BP Formulation
October 14, 2011
- CSMIC’s Kobayashi Questions Proposal to Freeze NHI Prices
October 12, 2011
- 17 Additional Products Eligible for PDSC Development Subsidies
October 12, 2011
- Industry to Seek Additional Data for Full Introduction of Premium for New Drug Development: Mr Negi
October 11, 2011
- OPMA to Develop Projects for Kansai Innovation Special area
October 11, 2011
- JACDS to Propose Reforms to Promote Switch-OTC Progress in Japan
October 11, 2011
- Association-managed Pharmacies Should Become “Home Healthcare Support Centers”: Mr Kodama of JPA
October 11, 2011
- JPA Announces FY2010 Results of Drug Event Monitoring for SU Drugs
October 11, 2011
- JPMA to Work with IFPMA to Tackle Non-communicable Diseases in Developing World
October 10, 2011
- Speed, Quality of Clinical Trials Have Increased: Mr Kawaguchi of JPMA
October 10, 2011
- Leading Biotech Clusters in Osaka, Munich Sign Partnership Agreement
October 5, 2011
- Permanent Introduction of Premium for New Drug Development Is an Option: Executive Director Miura of JPA
October 3, 2011
- Takeda “Will Be Able to Get Through” Power Shortages: Mr Hasegawa
October 3, 2011
- “Permanent Introduction of Premium for New Drug Development Premature”: CSIMC Member Adachi
September 30, 2011
- JPA, JSHP Announce Glossary of Standard Terminology for Drug Prescriptions
September 30, 2011
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…